BioTime, Inc. (NYSE MKT:BTX) announced that its subsidiary Asterias
Biotherapeutics, Inc. (OTCBB:ASTY) has received clearance from the U.S.
Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical
trial of its product, AST-OPC1, in patients with complete cervical
spinal cord injury.
for BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients With Cervical Complete Spinal Cord Injury investment picks